A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
← catalyst calendarNCT06433752 · readout in 2,052 d
Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
91
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-22 | actual | When the study began enrolling |
| Primary completion | 2032-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsing Multiple Sclerosis
- Multiple Sclerosis
Intervention
- Other: No Intervention
Primary outcome
what the primary-completion date above is the date OFAnnualized Relapse Rate (ARR)
measured Up to Week 96
Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed